Latest News and Press Releases

EXTON, Pa., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018.  Ms....

- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control -  - Tumor shrinkage observed in both injected and uninjected lesions,...

EXTON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug...

–  Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 ––  Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals,...

- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod - - Data demonstrate contribution of tilsotolimod to overcome resistance to ipilimumab in...

EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...

- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors - - Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to...

EXTON, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...

EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...

Abstract accepted for 2018 European Society of Medical Oncology Annual Meeting Cash runway into first quarter of 2020 EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc....